Johnson & Johnson Analysis: Boring, Slow Growing And Stable (Recession Proof)

Last Updated on May 8, 2023

Governments have currently implemented draconian measures to stop the coronavirus, leading to a wide global sell-off on the stock exchanges. Market drops are often a good thing if you have cash or if the companies have the liquidity to buy back shares and wither the storm.

The FED is printing almost insane amounts of money every day and EU states are going into debt to limit the number of deaths (on mostly unreliable data – only later will we be able to measure what was smart or not). Clearly, Western governments are completely unprepared for this pandemic.

Johnson & Johnson (JNJ) should be one of the safest performers in this environment. Below you find some notes I made this morning:

Business/segments:

• Consumer (17% of revenue): Personal healthcare in beauty, baby care, oral care etc. This includes OTC medicines like Zyrtec (allergy), Ibuprofen products, etc.
• Pharmaceutical (51% of revenue): Immunology, infectious diseases, neuroscience, oncology, cardiovascular/metabolism and pulmonary hypertension. These medicines are prescribed and distributed to retailers, wholesalers, hospitals, etc.
• Medical Devices (32 of revenue): Orthopaedic, surgery, interventional solutions and eye health. These are mainly ordered by professionals (nurses, hospitals, etc.)

JNJ sells to all corners of the world. The same goes for their production. 42.1% of sales is in the US, 18.5% in Europe, 15.6% in Asia, and 5.9% in the rest of the Western world.

Over the last two years, JNJ has invested about 15 billion in R&D to develop new drugs. Management focuses on markets it can hold a dominant position, among the three best, and divesting assets that don’t hold such positions.

Inside ownership or skin in the game:

All directors and officers own about 1.25 million shares, and even with compensation-controlled options, the ownership is below 1%. Alex Gorsky, the CEO, owns about 4 million shares, worth around 40 million.

Historical numbers:

	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Sales	63,747	61,897	61,587	65,030	67,224	71,312	74,331	70,074	71,890	76,450	81,581	82,059
Net earnings	12,949	12,266	13,334	9,672	10,853	13,831	16,323	15,409	16,540	1,300	15,297	15,119
EPS	4.57	4.40	4.78	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63
Operating cash flow	14,972	16,571	16,385	14,298	15,396	17,414	18,471	19,279	18,767	21,056	22,202	23,416
Free cashflow per share		5.02	4.3	4.43	4.65	5.08	5.3	4.79	6.71	6.76	7.31
Equity per share		18.37	20.66	20.95	23.33	26.25	25.06	25.82	26.02	22.43	22.44	22.59
LT debt	8,120	8,223	9,156	12,969	11,489	13,328	15,122	12,857	22,442	30,675	27,684	26,494
Dividend per share		1.93	2.11	2.25	2.40	2.59	2.76	2.95	3.15	3.32	3.54	3.75
Interest expense		451	455	571	532	482	533	552	726	934	1005	318
ROE %	30.460	24.247	23.567	16.945	16.742	18.677	23.401	21.657	23.488	2.161	25.5	25.400
ROIC % (Morningstar)			19.65	13.39	14.22	16.39	18.47	17.55	17.86	1.69	16.9	17.01

Revenue has grown 2.32% annually since 2008 (11 years) while operating cash flow has grown 4%.

The dividend:

Many own JNJ because of the dividend (which has been raised for over 30 years in a row). That is understandable, but most investors should know there are other ways to create “income”, like selling shares for example. The current yield as of writing is 3.2%, the highest yield since 2012. The payout ratio is about 50% of the free cash flow, and I would say the dividend is pretty safe.

Valuation:

I expect JNJ to be much less impacted by the coronavirus than most other companies. Since the outbreak, the stock has dropped from 150 to 120 (20%), and currently trading at 16 times last year’s free cash flow. The financial crisis little impacted JNJ in 2008/09, but it remains to be seen how the coronavirus affects earnings. I expect a drop, but I assume much of it is already discounted.

Moat:

To develop a new drug is immensely costly, mainly due to very tight regulations. Thus, developing a new drug requires a lot of capital, sometimes billions of USD. Regulation limits competition and I assume big pharma, which clearly JNJ is, has an advantage over much smaller and less capitalized drug companies. The diverse drug portfolio developed by JNJ means no drug has more than 13% of the segment’s sales, and obviously less on company-wide revenue.

Risk:

Most of the acquisitions have been small, in a category that can be labelled “bolt-on”, only occasionally every 5-6 years do they make a bigger acquisition. The biggest over the last ten years was Actelion for 30 billion back in 2017. M&A is difficult, but based on history it seems JNJ has managed this pretty good.

The pharma segment obviously is dependant on patents, and sales drop as soon a drug is no longer patented. The segment is the most profitable and it’s thus important that R&D allocates enough funds for the extreme costs of developing new drugs. Furthermore, many new drugs fail approval from the FDA (after spending billions in development), and this gives way to the “necessity” for some M&A.

Lawsuits are (unfortunately?) pretty common in the US, and JNJ is no exception and has ongoing lawsuits at all times, for example the talcum powder lawsuits.

Balance sheet:

Cash and liquid assets at 31.12.2019 were 12% of the assets, 20 billion. Long-term debt is at 26 billion (debt/equity is 0.5) and rated AAA, the highest rating together with Microsoft. The company has a rock-solid balance sheet and is unlikely to have any problems servicing the debt.

Conclusion:

JNJ is highly likely a boring but stable performer. During stressed times like today, it provides a safe haven and is unlikely to be hugely affected by the pandemic, except perhaps being forced to close some factories due to infection. However, this will pass.

What rate of return can you expect in JNJ over the next decade? I like to keep things simple and use late John Bogle’s very simple formula of calculating future returns over the next decade (or longer):

Dividend yield + earnings growth + multiple expansion = annual growth.

If we expect the same growth as over the last two decades, which is about 4%, and the same valuation in ten years’ time, we can expect 7.2% (3.2 + 4). Clearly, it will not set the world on fire.

I currently have no position in JNJ.

Disclosure: I am not a financial advisor. Please do your own due diligence and investment research or consult a financial professional. All articles are my opinion – they are not suggestions to buy or sell any securities.